Aviva’s Meridian Bioscience Inc VIVO Stock Holding History

Aviva’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,017	Closed	-$333K	–	1048
2022 Q4	$333K	Buy	+10,017	New	+$323K	﹤0.01%	968
2022 Q3	–	Sell	-72,567	Closed	-$2.21M	–	1087
2022 Q2	$2.21M	Sell	72,567 -13,818	-16%	-$374K	0.01%	749
2022 Q1	$2.24M	Buy	+86,385	New	+$2.05M	0.01%	796

Other funds holding VIVO

BTI

Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Aviva's VIVO Position: Q1 2023 in Review

Aviva sold out of Meridian Bioscience Inc (VIVO) in Q1 2023, closing a stake of 10,017 shares — an estimated $333K sold.

Aviva first reported a position in VIVO in Q1 2022 and held it in 3 quarters. The position peaked at $2.24M in Q1 2022. 2 funds tracked by Wall St. Rank hold VIVO as of Q1 2023.

Aviva reported no remaining Meridian Bioscience Inc position as of Q1 2023 after selling out during the quarter.
Aviva sold 10,017 Meridian Bioscience Inc shares in Q1 2023, an estimated $333K.
Aviva first reported a position in Meridian Bioscience Inc in Q1 2022 and held it in 3 quarters.
Aviva's Meridian Bioscience Inc position peaked at $2.24M in Q1 2022.
2 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q1 2023.

Based on Aviva's 13F filing for Q1 2023, filed 12 May 2023.